Biothera - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 45

Biothera – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Biothera - Product Pipeline Review - H2 2011” provides data on the Biothera’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biothera’s corporate website, SEC filings, investor presentations and featured press releases, both from Biothera and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biothera - Brief Biothera overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biothera human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biothera with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biothera’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Biothera’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biothera in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biothera’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biothera.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biothera and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Biothera; Biothera - Key Therapeutics; Biothera - Pipeline Overview and Promising Molecules; Biothera - News; Biothera - Latest Updates; Biothera - Pipeline; Biothera - Discontinued/Dormant Projects

List of Tables
List of Figures
Biothera Snapshot
Biothera Overview
Key Information
Key Facts
Biothera – Research and Development Overview
Key Therapeutic Areas
Biothera – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Combination Treatment Modalities
Biothera – Pipeline Products Glance
Biothera – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Biothera Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Biothera – Drug Profiles
Imprime PGG + Bevacizumab + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Imprime PGG + Cetuximab + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Imprime PGG + Erbitux
Product Description
Mechanism of Action
R&D Progress
Imprime PGG + Erbitux + Camptosar
Product Description
Mechanism of Action
R&D Progress
Biothera – Pipeline Analysis
Biothera – Pipeline Products by Therapeutic Class
Biothera - Pipeline Products By Target
Biothera – Pipeline Products by Route of Administration
Biothera – Pipeline Products by Molecule Type
Biothera – Recent Pipeline Updates
Biothera - Dormant Projects
Biothera - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AS1402
Biothera – Locations And Subsidiaries
Head Office
Recent Developments
Sep 30, 2008: Antisoma Initiates Phase II Trial Of AS1402 In Breast Cancer
Sep 30, 2008: Antisoma Starts Phase II Trial Of AS1402 In Breast Cancer
May 29, 2009: Biothera Releases Colorectal Cancer Study Results At ASCO
Jan 29, 2009: Biothera Expands Metastatic Colorectal Cancer Trial
Feb 28, 2008: Imprime PGG Synergistic With Avastin Against Cancer
Apr 19, 2011: Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress
Apr 19, 2011: Biothera's Phase II Lung Cancer Trials Achieve Stage 1 Goals
May 18, 2011: Biothera Initiates Dosing In Colorectal Cancer Phase III Trial
Mar 14, 2011: Biothera Initiates Phase I/II Clinical Trial In Chronic Lymphocytic Leukemia To Evaluate Combination Therapy With Imprime PGG
Oct 12, 2010: Biothera Reports Combination Of Imprime PGG And Erbitux Doubles Overall Response Rate In Colorectal Cancer Clinical Trial
Jun 10, 2009: Biothera Launches Clinical Trial In KRAS-Mutated Colorectal Cancer Patients
Aug 07, 2009: Antisoma Announces Discontinuation Of Development Of AS1402
Jul 06, 2010: Biothera Reports Combination Of Imprime PGG And Erbitux Doubles Therapeutic Response In Colorectal Cancer Patients In Phase Ib/IIa Trial
Jun 04, 2007: Imprime PGG Enhanced Effectiveness Of Avastin In Cancer Study
Financial Deals Landscape
Biothera, Deals Summary
Biothera, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Biothera Acquires AS1402 From Antisoma
Venture Financing
Biothera Raises $3.5 Million In Venture Financing
Biopolymer Engineering Secures $35 Million In Venture Financing
Partnerships
The E.T. Horn Enters Into Distribution Agreement With Biothera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Biothera – Pipeline by Therapy Area and Indication, H2 2011
Biothera – Pipeline by Stage of Development, H2 2011
Biothera – Combination Treatment Modalities in Pipeline, H2 2011
Biothera – Phase III, H2 2011
Biothera - Phase II, H2 2011
Biothera - Pipeline By Therapeutic Class, H2 2011
Biothera - Pipeline By Target, H2 2011
Biothera – Pipeline By Route of Administration, H2 2011
Biothera – Pipeline By Molecule Type, H2 2011
Biothera – Recent Pipeline Updates, H2 2011
Biothera - Dormant Developmental Projects, 2010
Biothera - Discontinued Pipeline Products, 2010
Biothera, Deals Summary
Biothera Acquires AS1402 From Antisoma
Biothera Raises $3.5 Million In Venture Financing
Biopolymer Engineering Secures $35 Million In Venture Financing
The E.T. Horn Enters Into Distribution Agreement With Biothera

List of Figures
Biothera – Pipeline by Therapy Area and Indication, H2 2011
Biothera – Pipeline by Stage of Development, H2 2011
Biothera – Combination Treatment Modalities in Pipeline, H2 2011
Biothera – Pipeline By Therapeutic Class, H2 2011
Biothera - Pipeline By Target, H2 2011
Biothera – Pipeline By Route of Administration, H2 2011
Biothera – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Analysis of Google Inc
• Amazon - Point of Realization in 2013?
• Insight into Samsung Electronics' Notebook PC Business Model
• Accenture - Profile - US